Teva and mAbxience Expand Partnership to Include New Oncology Biosimilar

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and mAbxience, a company majority-owned by Fresenius Kabi, have announced a new global licensing agreement to develop an anti PD-1 oncology biosimilar candidate. This agreement, which follows an initial partnership established in April 2024, aims to strengthen the collaborative efforts between the two companies in delivering affordable, high-quality biosimilar treatments for oncology care.

The strategic partnership between Teva and mAbxience is designed to address critical unmet needs in oncology by combining both companies' expertise and resources. The collaboration seeks to enhance innovation and accessibility in healthcare, offering solutions to patients around the globe. The licensing agreement grants exclusive rights for multiple markets, including Europe and the United States, aligning with mAbxience's strategy for global expansion.

This partnership is a significant step in Teva's Pivot to Growth strategy, which focuses on expanding its biosimilar portfolio through targeted partnerships and business development. By adding a new biosimilar to its extensive range, Teva continues to advance its commitment to providing cost-effective treatment options.

Under the terms of the agreement, mAbxience will be responsible for the development and production of the biosimilar in its state-of-the-art facilities in Spain and Argentina, which comply with current Good Manufacturing Practices (cGMP). Teva, on the other hand, will handle regulatory approvals and oversee the commercialization of the biosimilar in the designated markets, ensuring that patients worldwide can access this important oncology treatment.

Angus Grant, PhD, Executive Vice President of Business Development at Teva, expressed enthusiasm about the expanded collaboration. He emphasized that the agreement not only strengthens the alliance between Teva and mAbxience but also showcases their shared dedication to increasing access to essential oncology treatments. Grant highlighted the benefits of the partnership model, which optimizes development costs, leverages regulatory expertise, and utilizes Teva's extensive commercial capabilities to bring new treatment options to patients with serious medical conditions.

Jurgen Van Broeck, CEO of mAbxience, echoed these sentiments, noting that the second collaboration is a testament to the strength of the partnership and the shared vision of both companies. He reiterated mAbxience's commitment to making high-quality biosimilars accessible and improving healthcare outcomes globally.

Teva Pharmaceuticals is a global leader in the pharmaceutical industry, known for its extensive portfolio that combines generics expertise with innovative approaches. With over 120 years of commitment to improving health, Teva operates in 58 markets and employs approximately 37,000 people. The company's focus on scientific innovation and delivering quality medicines aims to improve health outcomes for millions of patients daily.

mAbxience, based in Spain, specializes in the development, production, and commercialization of biopharmaceuticals. Since August 2022, it has been majority-owned by Fresenius Kabi, transforming it into a global, vertically integrated biotechnology company. With over a decade of experience, mAbxience is dedicated to providing accessible and affordable medicines worldwide. The company operates three GMP-approved multi-product facilities in Europe and South America and has a strong presence in over 100 markets. mAbxience also offers Contract Development and Manufacturing Organization (CDMO) services, using advanced technology and innovative platforms to deliver integrated manufacturing solutions.